DOAJ Open Access 2017

Crizotinib in treatment of lung cancer

Arpita Singh Anubhuti Singh Kislay Kishore Ajay K Verma Surya Kant

Abstrak

Lung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer.

Topik & Kata Kunci

Nursing Homeopathy

Penulis (5)

Arpita Singh

Anubhuti Singh

Kislay Kishore

Ajay K Verma

Surya Kant

Format Sitasi

APA MLA BibTeX

Singh, A., Singh, A., Kishore, K., Verma, A.K., Kant, S. (2017). Crizotinib in treatment of lung cancer. https://doi.org/10.4103/mjmsr.MJMSR_62_16

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.4103/mjmsr.MJMSR_62_16

Informasi Jurnal

Tahun Terbit: 2017
Sumber Database: DOAJ
DOI: 10.4103/mjmsr.MJMSR_62_16
Akses: Open Access ✓